CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 123 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2023. The put-call ratio across all filers is 1.64 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $63,314,313 | -28.1% | 2,900,335 | +4.8% | 0.00% | -20.0% |
Q2 2023 | $88,003,526 | +15.0% | 2,768,277 | -11.8% | 0.01% | +25.0% |
Q1 2023 | $76,525,723 | -64.6% | 3,137,586 | -54.2% | 0.00% | -33.3% |
Q4 2022 | $215,999,798 | +181.1% | 6,848,440 | +151.8% | 0.01% | +20.0% |
Q3 2022 | $76,847,000 | +20.4% | 2,719,272 | +12.6% | 0.01% | +25.0% |
Q2 2022 | $63,839,000 | -15.7% | 2,414,474 | +11.7% | 0.00% | 0.0% |
Q1 2022 | $75,695,000 | +5.3% | 2,162,096 | -2.5% | 0.00% | +33.3% |
Q4 2021 | $71,883,000 | +12.7% | 2,217,248 | +2.6% | 0.00% | 0.0% |
Q3 2021 | $63,772,000 | +90.1% | 2,161,772 | +65.1% | 0.00% | +50.0% |
Q2 2021 | $33,550,000 | +162.2% | 1,309,519 | +40.5% | 0.00% | +100.0% |
Q1 2021 | $12,798,000 | – | 932,136 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,314,160,084 | 42.08% |
Perceptive Advisors | 10,088,385 | $220,229,445 | 7.35% |
Finepoint Capital LP | 563,345 | $12,297,821 | 6.12% |
Affinity Asset Advisors, LLC | 685,061 | $14,954,882 | 4.21% |
Paradigm Biocapital Advisors LP | 2,532,972 | $55,294,779 | 3.75% |
Logos Global Management LP | 700,000 | $15,281,000 | 2.04% |
Artal Group S.A. | 1,638,858 | $35,776 | 1.53% |
Rock Springs Capital Management LP | 2,529,116 | $55,210,602 | 1.48% |
GREAT POINT PARTNERS LLC | 215,000 | $4,693,450 | 0.86% |
Frazier Life Sciences Management, L.P. | 393,000 | $8,579,190 | 0.57% |